inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.
Company profile
Ticker
IKT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
IKT Securities Corporation ...
IKT stock data
Latest filings (excl ownership)
S-1
IPO registration
19 Apr 24
8-K
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
18 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
8-K/A
Departure of Directors or Certain Officers
2 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7 Feb 24
424B5
Prospectus supplement for primary offering
1 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
8-K
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
16 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
IKT
Earnings call transcript
2023 Q3
15 Nov 23
IKT
Earnings call transcript
2023 Q2
15 Aug 23
IKT
Earnings call transcript
2023 Q1
16 May 23
IKT
Earnings call transcript
2022 Q4
3 Apr 23
IKT
Earnings call transcript
2022 Q3
15 Nov 22
IKT
Earnings call transcript
2022 Q2
15 Aug 22
IKT
Earnings call transcript
2022 Q1
17 May 22
IKT
Earnings call transcript
2021 Q4
1 Apr 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.86 mm | 14.86 mm | 14.86 mm | 14.86 mm | 14.86 mm | 14.86 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.59 mm | 1.67 mm | 1.37 mm | 1.52 mm |
Cash used (since last report) | n/a | n/a | 10.85 mm | 11.38 mm | 9.34 mm | 10.35 mm |
Cash remaining | n/a | n/a | 4.02 mm | 3.48 mm | 5.53 mm | 4.51 mm |
Runway (months of cash) | n/a | n/a | 2.5 | 2.1 | 4.0 | 3.0 |
Institutional ownership, Q2 2023
32.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 3 |
Closed positions | 8 |
Increased positions | 0 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 2.56 bn |
Total shares | 2.07 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FiveT Investment Management | 1.34 mm | $971.00 k |
Armistice Capital | 496.55 k | $1.79 bn |
Vanguard | 88.31 k | $318.80 mm |
Blair William & Co | 57.89 k | $208.98 mm |
Redmond Asset Management | 20.98 k | $75.72 mm |
Edgewood Management | 16.67 k | $60.17 mm |
Geode Capital Management | 14.84 k | $51.64 mm |
Renaissance Technologies | 12.72 k | $46.00 k |
BCS Barclays | 11.46 k | $41.00 k |
STT State Street | 10.08 k | $35.09 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Garth Lees-Rolfe | Stock Option Common Stock | Grant | Acquire A | No | No | 2.16 | 90,000 | 194.40 k | 90,000 |
1 Apr 24 | Milton H. Werner | Stock Option Common Stock | Grant | Acquire A | No | No | 2.16 | 45,000 | 97.20 k | 45,000 |
1 Mar 23 | Joseph Frattaroli | Stock Option Common Stock | Grant | Acquire A | No | No | 0.74 | 90,000 | 66.60 k | 90,000 |
1 Mar 23 | Milton H. Werner | Stock Option Common Stock | Grant | Acquire A | No | No | 0.74 | 210,000 | 155.40 k | 210,000 |
News
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
22 Apr 24
Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs; Says 201 Trial Is ~75% Enrolled
18 Apr 24
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
27 Mar 24
HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target
7 Mar 24
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
5 Mar 24
Press releases
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
18 Apr 24
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
3 Apr 24
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
27 Mar 24
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
7 Mar 24
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
7 Feb 24